Skip to main content
All lobbying filings

HALEON US HOLDINGS LLC

Lobbying for HALEON US HOLDINGS LLC · Consumer health care company

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · New Jersey · House · Senate · $240,000.00 expenses · posted Apr 20, 2026

Official filing document

 Bills named in this filing 6
  • S 3122
    Better FDA Act of 2025
  • S 2529
    A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription …
  • S 3677
    Dietary Supplement Listing Act of 2026
  • HR 6868
    ACCESS Through OTC Innovation Act
  • HR 5371
    Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions …
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
 Lobbying activity 13
Environment/Superfund

General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings.

Foreign Relations

General review and monitoring of U.S. diplomatic relations.

Consumer Issues/Safety/Products

General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare, over the counter settings, and protection of personally identifiable information.

Copyright/Patent/Trademark

General monitoring of issues and administrative action related to intellectual property protection.

Health Issues

General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments. General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.

Medicare/Medicaid

General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.

Taxation/Internal Revenue Code

General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA; General review and monitoring of implementation of One Big Beautiful Bill Act (OBBBA)

Trade (domestic/foreign)

Monitor and review of issues related to the Section 301 tariffs; Monitor and review of issues related to the Section 232 tariffs; Monitor and review of issues related to reciprocal tariffs under International Economic Emergency Powers Act; General monitoring and review of Executive Order 14257 and impacts on OTC products; General monitoring and review of legislative and executive actions on international trade policy related to tariffs, import/export concerns; General monitoring of legislative and administrative action related to review of the United States-Mexico-Canada Agreement (USMCA); and General review and monitoring of global supply chain concerns

Food Industry (safety, labeling, etc.)

General monitoring and review of issues and executive actions related to or impacting multivitamins and nutrition.

Family issues/Abortion/Adoption

General review of legislative and administration action related to pediatric over-the-counter medication concerns.

Pharmacy

General review and monitoring of processes impacting over-the-counter switches.

Tobacco

General review and monitoring on efforts aimed at preventing youth consumption of tobacco products; General review and monitoring of smoking cessation and over-the-counter alternatives for adult consumers.

Manufacturing

General issues related to the manufacturing and supply chain resiliency of over-the-counter medications, specifically as it relates to additional domestic production of healthcare products; General monitor and review of legislative and administrative action related to domestic supply chain and manufacturing capabilities.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem